Literature DB >> 397657

The eighth Frederick H. Verhoeff Lecture. presented by saiichi mishima, MD Behçet's disease in Japan: ophthalmologic aspects.

S Mishima, K Masuda, Y Izawa, M Mochizuki, K Namba.   

Abstract

The problems of Behçet's disease in Japan have been reviewed with particular emphasis on the ophthalmologic aspects: the historical background for the Japanese works, diagnostic critieria, epidemiology, some statistics, ocular symptomatology, ocular histopathology, etiology, pathophysiology, and treatment. Behçet's disease is the most frequent entity in endogenous uveitis in Japan. Patients are found throughout the country, and the prevalence rate averages seven to eight per 100,000 population: the rate is higher in the northern than in the southern districts. The diagnosis is made on the basis of a combination of clinical symptoms that are divided into the major and minor criteria symptoms. The major criteria comprise the ocular involvement, aphthous ulcers of the oral mucous membrane, genital ulcers, and skin lesions. These symptoms recur often as attacks and the disease follows a chronic course. The ocular involvement is found in 83% to 95% in males and 67% to 73% in females; the male to female ratio in the number of patients is 1.78. Both into the anterior segment type and the fundus and panophthalmic types. The anterior segment type shows serous iridocyclitis with the classic type of hypopyon appearing in about 12% of the attacks. This type is found in about 20%, more often in females than in males, and the visual prognosis is more favorable than in the fundus and panophthalmic types. In the latter two types, attacks of retinal angitis resulting in intensive retinal edema, yellowish-white exudate, and hemorrhages recur particularly in the macular region, and the visual prognosis is poor. More than 50% of male patients lose visual acuity to less than 0.1 in five years, but this is the case in only 10% of female patients. Consequently, Behçet's disease is the cause of blindness in about 12% of acquired blindness in adults. The ocular histopathology during the attack is characterized by severe angitis with intensive infiltration of neutrophil leucocytes largely in the uveal tract and the retina; the latter is severely affected and loss of visual cells and other neural elements results. The etiology of this disease still remains unknown but genetic predisposition is suggested since this disease is strongly linked with HL-A-B5. Environmental factors are also considered. Various abnormalities are found in the blood chemistry, blood cells (particularly in neutrophil leucocytes), immunologic mechanism, fibrinolytic and blood clotting system, and hormonal system. Chemotractic factors are found in the aqueous humor. These changes are particulary enhanced just before and during the ocular attacks. Systemic corticosteroids are deleterious to the visual prognosis, but cyclophosphamide and colchicine appear to suppress attacks and help patients maintain the visual acuity. However, these drugs are toxic, particulary to the reproductive organs, and the patients must be informed of this side effect and be allowed to make a decision before they are used.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 397657      PMCID: PMC1311704     

Source DB:  PubMed          Journal:  Trans Am Ophthalmol Soc        ISSN: 0065-9533


  71 in total

1.  [Determination of HL-A antigens in Behcet's disease].

Authors:  E Rosselet; Y Saudan; M Jeannet
Journal:  Ophthalmologica       Date:  1976       Impact factor: 3.250

2.  Immunosuppressive treatment of Behcet's disease.

Authors:  K Aoki; S Sugiura
Journal:  Mod Probl Ophthalmol       Date:  1976

3.  Clinical Studies on Behçet's Syndrome.

Authors:  Y Oshima; T Shimizu; R Yokohari; T Matsumoto; K Kano; T Kagami; H Nagaya
Journal:  Ann Rheum Dis       Date:  1963-01       Impact factor: 19.103

4.  So-called triple-symptom complex of Behçet.

Authors:  E W P THOMAS
Journal:  Br Med J       Date:  1947-01-04

5.  [Serum antibodies to various pathogenic agents and lymphocytic transformation in Behçet disease].

Authors:  S Sugiura; K Aoki; K Fujioka; M Kono; N Sakurada
Journal:  Nippon Ganka Gakkai Zasshi       Date:  1972-08

6.  [Studies on fibrinolytic activity in Behçet's disease. 3. An approach by affinity chromatography (author's transl)].

Authors:  K Saito
Journal:  Nippon Ganka Gakkai Zasshi       Date:  1973-09

Review 7.  [Pathogenesis and treatment of Behcet's disease].

Authors:  S Oniki
Journal:  Nippon Ganka Gakkai Zasshi       Date:  1974-11-10

8.  The use of chlorambucil in intractable idiopathic uveitis.

Authors:  W A Godfrey; W V Epstein; G R O'Connor; S J Kimura; M J Hogan; R A Nozik
Journal:  Am J Ophthalmol       Date:  1974-09       Impact factor: 5.258

9.  Treatment of Behcet disease with chlorambucil. A follow-up report.

Authors:  J G Mamo
Journal:  Arch Ophthalmol       Date:  1976-04

10.  [HLA antigens in the patients with Behcet's disease, sarcoid-uveitis, and endogeneous uveitis (author's transl)].

Authors:  S Okinami; M Hayashi; M Uyama
Journal:  Nippon Ganka Gakkai Zasshi       Date:  1977-01-10
View more
  34 in total

Review 1.  Behçet's disease.

Authors:  V Kontogiannis; R J Powell
Journal:  Postgrad Med J       Date:  2000-10       Impact factor: 2.401

2.  [Epidemiology of ocular involvement in Adamantiades-Behçets disease].

Authors:  C E Kneifel; A-K Köhler; A Altenburg; C C Zouboulis; L Krause
Journal:  Ophthalmologe       Date:  2012-06       Impact factor: 1.059

3.  Anterior uveitis and hypopyon.

Authors:  L P D'Alessandro; D J Forster; N A Rao
Journal:  Trans Am Ophthalmol Soc       Date:  1991

4.  Ocular involvement in Adamantiades-Behçet's disease in Berlin, Germany.

Authors:  Lothar Krause; Anne-Katrin Köhler; Andreas Altenburg; Nestor Papoutsis; Christos C Zouboulis; Uwe Pleyer; Andrea Stroux; Michael H Foerster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-11-04       Impact factor: 3.117

5.  Use of laser flare-cell photometry to quantify intraocular inflammation in patients with Behçet uveitis.

Authors:  Ilknur Tugal-Tutkun; Kürsat Cingü; Nur Kir; Baris Yeniad; Meri Urgancioglu; Ahmet Gül
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-05-27       Impact factor: 3.117

6.  Fundus changes in Behcet's disease.

Authors:  L N Dominguez; A R Irvine
Journal:  Trans Am Ophthalmol Soc       Date:  1997

7.  Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis.

Authors:  I Kötter; M Zierhut; A K Eckstein; R Vonthein; T Ness; I Günaydin; B Grimbacher; S Blaschke; W Meyer-Riemann; H H Peter; N Stübiger
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

8.  Hypopyon in patients with uveitis.

Authors:  Ali A Zaidi; Gui-Shuang Ying; Ebenezer Daniel; Sapna Gangaputra; James T Rosenbaum; Eric B Suhler; Jennifer E Thorne; C Stephen Foster; Douglas A Jabs; Grace A Levy-Clarke; Robert B Nussenblatt; John H Kempen
Journal:  Ophthalmology       Date:  2009-12-14       Impact factor: 12.079

9.  Cyclophosphamide for ocular inflammatory diseases.

Authors:  Siddharth S Pujari; John H Kempen; Craig W Newcomb; Sapna Gangaputra; Ebenezer Daniel; Eric B Suhler; Jennifer E Thorne; Douglas A Jabs; Grace A Levy-Clarke; Robert B Nussenblatt; James T Rosenbaum; C Stephen Foster
Journal:  Ophthalmology       Date:  2009-12-06       Impact factor: 12.079

10.  Clinical features of Behcet's disease in Mongolia: a multicenter study.

Authors:  Javzandulam Balt; Baasankhuu Jamyanjav; Sarantuya Jav; Zulgerel Dandii; Chimedlkhamsuren Ganbold; Yukihiro Horie; Anton Lennikov; Osamu Uehara; Shigeaki Ohno; Nobuyoshi Kitaichi
Journal:  Clin Rheumatol       Date:  2020-03-10       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.